RxDoctor Payments Data

Richard Mueller, MD

Cardiovascular Disease · New York, NYNPI 1285616094

Payments from drug & device makers

$50,201in general payments, 2019–2025

Across 358 payments — averaging $140.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$45K
  • Novartis$915
  • Amgen$773
  • Bardy Diagnostics, Inc.$545
  • Boehringer Ingelheim$540
  • Amarin Pharma, Inc.$455
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$39,85079%
  • Travel & lodging$1,2452%
  • Food & beverage$8,33317%
  • Education$270%
  • Other$4471%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,201 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$414,512
Medicare patients
179
Services billed
3,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban141$171,838
EntrestoSacubitril/Valsartan81$108,758
EliquisApixaban86$97,110
JardianceEmpagliflozin27$41,376
Repatha SureclickEvolocumab63$34,647
VascepaIcosapent Ethyl32$27,376
FarxigaDapagliflozin Propanediol13$15,815
Triamcinolone Acetonide13$6,865
Icosapent Ethyl19$4,268
Metoprolol Succinate227$3,539
Rosuvastatin Calcium193$2,768
Nebivolol Hcl56$2,689
Midodrine Hcl38$1,742
Atorvastatin Calcium171$1,704
Colchicine26$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$44,601$171,838141 claims
NovartisEntresto$915$108,75881 claims
PfizerEliquis$390$97,11086 claims
Boehringer IngelheimJardiance$540$41,37627 claims
AstraZenecaFarxiga$401$15,81513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →